Drug Profile
Doxorubicin liposomal - Insys Therapeutics
Alternative Names: Doxorubicin - liposome encapsulated; LED; Liposomal doxorubicin - Insys Therapeutics; PNU 108112; PNU 112 ONC 0354Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator Georgetown University
- Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
- Mechanism of Action P-glycoprotein inhibitors; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Prostate cancer
Most Recent Events
- 11 Jan 2008 Discontinued - Phase-III for Breast cancer in USA (unspecified route)
- 11 Jan 2008 Discontinued - Phase-III for Prostate cancer in USA (unspecified route)
- 21 Sep 2004 Pfizer has terminated its worldwide licence for LED